Skip to Main Content

Thomas Hope

MD

Radiologist
Radiologic therapy researcher and avid hiker

Dr. Thomas Hope is a radiologist and nuclear medicine physician (an expert in medical applications of radioactive substances). He specializes in neuroendocrine tumors, with a focus on peptide receptor radionuclide therapy, which targets these cancer cells with a high dose of radiation. He has a special interest in molecular imaging and in treating cancer using the targeted, individualized techniques of precision medicine.

In addition to working with patients, Hope conducts research on novel radiopharmaceuticals, or new radioactive imaging substances that can help physicians locate tumors. He also works on combining different imaging modalities – such as positron emission tomography and MRI – to stage cancer in patients.

Hope received his medical degree from Stanford University School of Medicine. He completed a residency in diagnostic radiology at UCSF. He then completed a fellowship in nuclear medicine and body MRI at Stanford.

Hope is a member of the Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging, Society of Abdominal Radiology and International Society for Magnetic Resonance in Medicine.

  • Education

    Stanford University School of Medicine, 2007

  • Residencies

    UCSF Medical Center, Diagnostic Radiology, 2012

  • Fellowships

    Stanford Hospital and Clinics, Nuclear Medicine and Body MRI , 2013

  • Board Certifications

    Nuclear Medicine, American Board of Nuclear Medicine

    Diagnostic Radiology, American Board of Radiology

  • Academic Title

    Associate Professor

Where I see patients (4)

    Selected research

    Decorative Caduceus

    18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas

    Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology as compared to sestamibi imaging. Location of parathyroid adenoma at imaging as read by three blinded readers, will be ...

    Recruiting

    Decorative Caduceus

    A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)

    Incidence of adverse events, serious adverse events, and clinical laboratory abnormalities defined as dose-limiting toxicities (DLTs)

    Recruiting

    Decorative Caduceus

    Imaging of Solid Tumors Using 68Ga-FAP-2286

    The frequency and severity of treatment emergent adverse events following 68Ga-FAP-2286 injection will be descriptively reported as classified and graded by National Cancer Institute Common Terminology Criteria for Adverse Events ...

    Recruiting

    Decorative Caduceus

    Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286

    Proportion of participants with Adverse Events, as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 will be reported.

    Recruiting

    Decorative Caduceus

    Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors

    Radiologists will classify lesions based on imaging as either having recurrent disease or not having recurrent disease. True Positives (TP) are defined as an FET PET read positive for tumor and pathology/follow-up demonstrates tum...

    Recruiting

    Share